

Start	End	Topic	Speakers
09:00	09:20	Neurogenic lower urinary tract (LUT) dysfunction	<ul style="list-style-type: none"> <li>John Heesakkers</li> </ul>
09:20	09:30	Discussion	All
09:30	09:50	Diagnostic workup - How informative are basic diagnostics, are urodynamics essential?	<ul style="list-style-type: none"> <li>Marcio Averbeck</li> </ul>
09:50	10:00	Discussion	All
10:00	10:10	How to maintain normal renal function, how to achieve continence/to manage incontinence	<ul style="list-style-type: none"> <li>Helmut Madersbacher</li> </ul>
10:10	10:30	Management of the overactive detrusor, combined with overactive sphincter, underactive sphincter and normal sphincter	<ul style="list-style-type: none"> <li>Thomas Kessler</li> </ul>
10:30	11:00	Break	None
11:00	11:10	Discussion	All
11:10	11:30	Management of the underactive (acontractile) detrusor, combined with overactive sphincter, underactive sphincter and normal sphincter	<ul style="list-style-type: none"> <li>Helmut Madersbacher</li> </ul>
11:30	12:00	Discussion	All

### **Aims of course/workshop**

The main focus will be on the every-day care of a patient with neurogenic bladder and on the therapy which is available in every centre.

Having participated in this course, which will also include case presentations, you should have a basic knowledge on neurogenic lower urinary tract dysfunction, its pathophysiology and its diagnostic work-up, moreover you should be aware what can be offered to the individual patient nowadays.

**Aims of course/workshop**

In the first part information on neurophysiology of the lower urinary tract and on pathophysiology related to cerebral, spinal and peripheral lesions and how they are reflected in clinical symptoms are provided. Thereafter a standard diagnostic approach will be presented and the value of the classic urodynamic techniques discussed. In the second part an overview on the therapeutic strategies in 2013 in patients (1) with an overactive detrusor and (2) with an underactive detrusor, each combined either with an underactive sphincter, an overactive sphincter or a normal sphincter will be given.

**Key learning points**

The main focus will be on the every-day care of a patient with neurogenic bladder and on the therapy which is available in every centre.

**Concluding key points**

Having participated in this course, which will also include case presentations, you should have a basic knowledge on neurogenic lower urinary tract dysfunction, its pathophysiology and its diagnostic workup, moreover you should be aware what can be offered to the individual patient nowadays.

## **Neurogenic Lower Urinary Tract Dysfunction**

– *from Neurophysiology via Pathophysiology to Clinics*

John PFA Heesakkers, MD PhD

Urologist

Radboud University Nijmegen MC

Nijmegen

The Netherlands

[j.heesakkers@uro.umcn.nl](mailto:j.heesakkers@uro.umcn.nl)

Acknowledgement to:

Yasuhiko Igawa, MD, PhD

Associate Professor, Department of Urology

Shinshu University School of Medicine

Matsumoto

Japan

[yxigawa@hsp.md.shinshu-u.ac.jp](mailto:yxigawa@hsp.md.shinshu-u.ac.jp)

## **INTRODUCTION**

The lower urinary tract (LUT), the urinary bladder and urethra, serves two reciprocal functions: storage of urine without leakage and periodic evacuation of urine. These two functions depend on central as well as peripheral autonomic and somatic neural pathways,<sup>1, 2</sup> but also on voluntary control which requires the participation of higher centers in the brain. Because of the complex neural regulations, the central and peripheral nervous control of the LUT is prone to a variety of neurological disorders. In this lecture the principals of neuronal control of the LUT function will be summarized as well as the pathophysiology of neurogenic LUT dysfunction in specific lesions.

## **NEUROPHYSIOLOGY OF THE LOWER URINARY TRACT**

### **Normal LUT function**

The LUT function can be divided in storage and voiding functions. Normal storage function includes 1) sensation bladder fullness, 2) postpone urination, 3) maintaining continence and 4) low bladder pressure. Normal voiding function means to void voluntarily and smoothly without straining or post-void residual.

### **Reflex pathways controlling urine storage and voiding**

Coordinated activities of the peripheral nervous system innervating the LUT during urine storage and voiding depend on multiple reflex pathways organized in the brain and spinal cord. The central pathways regulating LUT function are organized as on-off switching circuits that maintain a reciprocal relationship between bladder and its outlet.<sup>1-3</sup>

*The storage phase*

The accommodation of the bladder to increasing volumes of urine is primarily a passive phenomenon dependent on the intrinsic properties of the detrusor.<sup>1-4</sup> In addition to this passive accommodation mechanism, the afferent activity induced by bladder distention can trigger reflex activation of the sympathetic outflow to the LUT. It contributes to the storage mechanism that inhibits the parasympathetic efferent outflow to the bladder and promotes closure of the urethra through activation of  $\alpha_{1A}$ -adrenoceptors. Furthermore it facilitates relaxation of the detrusor via activation of  $\beta_2$ -adrenoceptors<sup>4</sup> (**Figure 1A**). This reflex is organized in the lumbosacral spinal cord. During bladder filling, the bladder afferent input also activates the pudendal motoneurons innervating the external urethral sphincter (EUS)<sup>3, 5</sup> and increases EUS activity. The EUS motor neurons are also activated by urethral/perineal afferents in the pudendal nerve<sup>6</sup>. These excitatory sphincter reflexes are organized in the spinal cord. Moreover, a supraspinal urine storage center located in the dorsolateral pons sends descending excitatory inputs to the EUS motoneurons to increase urethral resistance<sup>7,8</sup> (**Figure 1A**).

### *The voiding phase*

The storage phase can be switched to the voiding phase either involuntarily or voluntarily. When bladder volume reaches the micturition threshold, bladder afferents in the pelvic nerves trigger the micturition by acting on neurons in the sacral spinal cord, which then send their axons rostrally to the periaqueductal gray (PAG), which in turn communicates with the pontine micturition center (PMC)<sup>9, 10</sup>. Activation of the PMC reverses the pattern of efferent outflow to the LUT, inhibiting sympathetic and somatic pathways and activating parasympathetic pathways. The voiding phase consists of an initial relaxation of the urethral sphincter followed by a contraction of the bladder. Thus voiding reflexes depend on a spinobulbospinal pathway (**Figure 1B**). Secondary reflexes elicited by urine flow into the urethra also facilitate bladder emptying.<sup>1,3</sup> Inhibition of EUS activity during voiding depends, at least in part, on supraspinal mechanisms.

### **Peripheral and spinal pathways**

The peripheral nervous mechanisms for bladder emptying and urine storage involve efferent and afferent signaling in pelvic (parasympathetic), hypogastric (sympathetic) and pudendal (somatic) nerves.<sup>1,2</sup> (**Figure 2**).

### *Efferent pathways of the LUT*

#### 1. Parasympathetic pathways

Pelvic parasympathetic nerves, which arise at the sacral spinal cord ( $S_2$ - $S_4$ ), provide an excitatory input to the bladder and an inhibitory input to the bladder neck and urethral smooth muscle to eliminate urine<sup>1, 2, 11</sup> (**Figure 2**). Parasympathetic preganglionic neurons send axons to peripheral ganglia. Parasympathetic postganglionic neurons in humans are located in the bladder wall.<sup>3</sup> Parasympathetic postganglionic nerve terminals release

Acetylcholine (ACh), which can excite muscarinic receptors in the detrusor smooth muscle cells, leading to bladder contractions.<sup>12,13</sup> The postganglionic parasympathetic input to the urethra elicits inhibitory effects mediated at least in part through the release of nitric oxide (NO), which directly relaxes the urethral smooth muscle.<sup>3, 14, 15</sup> Therefore, the excitation of sacral parasympathetic efferent pathways induces a bladder contraction and urethral relaxation to promote bladder emptying during micturition.

## 2. Sympathetic pathways

Hypogastric sympathetic nerves, which arise at the thoraco-lumbar level of the spinal cord (Th<sub>11</sub>-L<sub>2</sub>), provide a noradrenergic inhibitory input to the bladder and excitatory input to the urethra to facilitate urine storage<sup>3</sup> (**Figure 2**). The sympathetic activation causes inhibition of the parasympathetic pathways at spinal and ganglionic levels, and releases noradrenaline (NA) from its postganglionic terminals, which elicit relaxation the bladder body and contractions of the bladder neck and urethral smooth muscle<sup>3</sup>.

## 3. Somatic pathways

Somatic efferent motoneurons which activate the external striated urethral sphincter muscle and the pelvic floor muscle are located along the lateral border of the ventral horn in the sacral spinal cord (S<sub>2</sub>-S<sub>4</sub>), commonly referred to as the Onuf's nucleus<sup>16</sup> (**Figure 2**). The somatic motoneurons send axons into the pudendal nerves. Combined activation of sympathetic and somatic pathways increases bladder outlet resistance and realises urinary continence.

### *Afferent pathways of the LUT*

The pelvic, hypogastric, and pudendal nerves also contain afferent axons that transmit information from the LUT to the spinal cord (**Figure 2**).<sup>1, 2, 17, 18</sup> The pelvic afferent nerves, which monitor the volume of the bladder and intravesical pressure, consist of small myelinated A $\delta$  and unmyelinated C fibers. Normal micturition reflex is mediated by myelinated A $\delta$  fibers, which respond to bladder distention and active contraction<sup>3, 18, 19</sup> (**Figure 3**). The activation threshold for A $\delta$  fibers is 5-15 cmH<sub>2</sub>O<sup>1</sup>. C-fiber afferents have a high mechanical threshold and are usually unresponsive to mechanical stimuli such as bladder distention<sup>19</sup> and therefore have been termed as "silent C fibers". However, these fibers respond primarily to chemical, noxious, or cold stimuli. During inflammation or neuropathic conditions, there is recruitment of C-fiber bladder afferents, which form a new afferent pathway that can cause detrusor overactivity and bladder pain<sup>20</sup> (**Figure 3**).

### **Brainstem (Pons)**

The dorsal pontine tegmentum has been established as an essential control center for micturition and called as the "pontine micturition center (PMC)" or the "M region" due to its median location.<sup>10, 21, 22</sup> Brain imaging studies have revealed increase in blood flow in this region of the pons during micturition.<sup>23</sup> Neurons in the PMC provide direct synaptic inputs to sacral PGN, as well as to GABA-nergic neurons in the sacral dorsal commissure (DCM).<sup>21</sup> The former neurons carry the excitatory outflow to the bladder, whereas the latter neurons are

thought to be important in mediating an inhibitory outflow on EUS motoneurons during micturition<sup>24</sup>. As a result of these reciprocal connections, the PMC can promote coordination between the bladder and urethral sphincter. In the cat, another area, located in the ventrolateral pontine tegmentum and is called the “L-region”, which controls the motoneurons of the pelvic floor, including the external urethral sphincter.<sup>25</sup> This region might be considered as the pontine storage center (**Figure 1A**). In humans the laterally located L-region is especially active in volunteers who tried but did not succeed to micturate.<sup>25, 26</sup>

### **Suprapontine pathways**

Studies in humans indicate that voluntary control of urine storage and voiding depends on connections between the frontal cortex and the septal/preoptic region of the hypothalamus as well as connections the paracentral lobule and the brainstem.<sup>1, 3</sup> Lesions to these areas of cortex exhibit detrusor overactivity (DO) because of lack of cortical inhibitory control. Brain imaging studies in right-handed both male and female volunteers have demonstrated decreased blood flow in the right anterior cingulate gyrus during urine withholding prior micturition and increased blood flow in the right dorsomedial pontine tegmentum, in the PAG, in the hypothalamus and in the right inferior frontal gyrus during voiding.<sup>23, 26, 27</sup> It has been implicated that the midbrain PAG receives bladder filling information, and the hypothalamus has a role in the beginning of micturition.<sup>28</sup> Furthermore, the human cingulate and prefrontal cortices are activated during both micturition and continence, indicating that these areas are important for the onset of micturition, but not for the reflex itself.

## **PATHOPHYSIOLOGY OF THE LOWER URINARY TRACT DYSFUNCTION**

When a neurological lesion is present, the type of LUT dysfunction roughly depends on the site and the extent of the lesion<sup>29</sup>.

Neurological pathology can be divided in 1) suprapontine, 2) brainstem (pontine), 3) suprasacral spinal cord, and 4) sacral and subsacral (cauda equine and peripheral nerve) lesions (**Figure 4**). Madersbacher et al described the common patterns of neurogenic detrusor-sphincter dysfunction in a diagram associated with these lesions (**Figure 5**).<sup>30</sup>

### **Suprapontine lesions**

Patients with lesions above the pons commonly demonstrate DO caused by lack of cortical inhibitory control, but they preserve coordinated synergic sphincter function (**Figure 5-A**). However, these patients sometimes may purposely increase sphincter activity during an overactive detrusor contraction to avoid urgency incontinence<sup>31</sup>. Typical suprapontine lesions include cerebro-vascular accident (CVA), dementia, brain tumors, and cerebral palsy.

#### *Cerebro-vascular accident (CVA)*

The most common LUT symptoms after stroke are nocturia (36%), urge incontinence (29%) and difficulty in voiding (25%)<sup>32</sup>. There is a positive correlation between the occurrence of

LUT dysfunction and hemiparesis<sup>32</sup>. Urodynamic studies revealed DO in 68%, uninhibited sphincter relaxation in 36%<sup>32</sup>. In patients with brainstem strokes, voiding symptoms are more predominant<sup>33</sup>.

### **Brainstem (pontine) lesions**

As the pontine micturition center (PMC) and the lateral storage centre are located in the brain stem, lesions of this area demonstrate a variety of LUT dysfunction. Both storage and voiding dysfunctions often occur simultaneously. The common diseases of this region include Parkinson's disease, multiple system atrophy (MSA), and multiple sclerosis.

#### *Parkinson's disease*

LUT dysfunction occurs in 37-71% of patients<sup>39, 40</sup>. Storage symptoms were observed in 28%, voiding symptoms in 11%, and both symptoms in 21%<sup>40</sup>. The frequency of LUT symptoms correlated with the severity of the disease, but not with the duration of the illness or sex<sup>40</sup>. DO was observed in 81%, external sphincter relaxation failure in 33%, and underactive detrusor in 66% of women and 40% of men<sup>41</sup>.

#### *Multiple system atrophy (MSA)*

MSA involves various syndromes resulted from degeneration of neurons and associated fibers of motor and extrapyramidal systems including the cerebellum and brain stem. LUT symptoms often precede orthostatic hypotension and other autonomic nervous system symptoms in MSA patients<sup>42</sup>. Almost 100% of MSA patients have some kind of LUT symptoms<sup>43, 44</sup>. The most common urodynamic abnormalities are abnormal sphincter EMG (in 82-91%)<sup>42, 44, 45</sup>, DO (in 56%)<sup>44</sup>, DSD (in 45-47%)<sup>44, 46, 47</sup>, uninhibited external sphincter relaxation (in 33%)<sup>44</sup>, and underactive detrusor (in 71% of women and 63% of men)<sup>44</sup>. Significant PVR is observed in about half of MSA patients<sup>48</sup>.

### **Suprasacral spinal cord lesions**

Spinal lesions mostly cause simultaneous dysfunction of the detrusor and the sphincter. In suprasacral spinal cord lesions a typical pattern of the LUT dysfunction is DO associated with DSD (**Figure 5-B**). If the lesion is complete, sensation of bladder filling disappears. Basically spontaneous reflex voiding is possible, however, it is uncontrolled, causing reflex incontinence, and unphysiological. DSD leads to unbalanced voiding with the possibility of a dangerous high pressure situation. While most traumatic spinal cord lesions give LUT dysfunction which can be predicted fairly well from the level and completeness of injury, the LUT dysfunction in many other neurological disorders such as myelomeningocele are more difficult to categorise<sup>29</sup> (**Figure 5-B, C, E & F**).

#### *Spinal cord injury (SCI)*

DO was demonstrated in 95%<sup>49</sup>, and DSD in 68%<sup>50</sup> of the patients with suprasacral lesions. In patients with sacral lesion, an acontractile detrusor was found in 86%, and low compliance in 79%<sup>49</sup>. Upper urinary tract changes were observed in 30-42% of SCI patients<sup>51, 52</sup>.

### *Multiple sclerosis (MS)*

The LUT dysfunction is mainly due to spinal lesions, although brain lesions may contribute<sup>30</sup>. Impairment of neurological function results from demyelinating plaques of the white matter of the brain and spinal cord, especially the posterior and lateral columns of the cervical cord. The prevalence of LUT dysfunction in MS patients is 33-52%, and its incidence is related to the disability status<sup>53</sup>. Urodynamic studies revealed DO in 44-99%, DSD in 6-66%, and detrusor underactivity in 31-38%<sup>54-56</sup>. The upper urinary tract is rarely involved<sup>57</sup>.

### **Sacral and subsacral (cauda equina and peripheral nerves) lesions**

Lesions of conus causing dysfunction of the sacral parasympathetic neurons and the EUS motoneurons are categorized as the same group as subsacral (cauda equina and peripheral nerves) lesions. For complete sacral or subsacral lesions, classically named as lower motor neuron lesions, loss of bladder sensation and acontractile detrusor with incompetent urethra are characteristic (**Figure 5-E**). However, acontractile detrusor combined with normal or overactive urethra may occur in lesions, comprising the conus and nearby area above (**Figure 5-D & F**). In lumbo-sacral lesions, especially in myelomeningocele, overactive detrusor combined with incompetent urethra sometimes occur (**Figure 5-C**). Subsacral (cauda equina and peripheral nerves) lesions are often incomplete and associated with a variety of combination patterns of the detrusor and urethral dysfunctions. For example, in case of pelvic nerve plexus injury after radical pelvic organ surgery, if the pudendal nerves remain intact, impaired bladder sensation and underactive/acontractile detrusor may be combined normally functioning urethra (**Figure 5-D**). On the other hand, the pudendal nerves are selectively disrupted, for instance, in traumatic pelvic fracture, incompetent urethra may occur with normal detrusor function (**Figure 5-H**)

### *Myelodysplasia (Myelomeningocele MMC) and spina bifida*

The incidence of LUT dysfunction is very high (>90%) in MMC patients<sup>29</sup>. Most have LUT dysfunction leading to incontinence and/or upper tract deterioration.

### *Diabetes Mellitus*

There are no proper epidemiological studies on the incidence of diabetes-related LUT dysfunction. Neurogenic LUT dysfunction occurs in 43-87% of insulin-dependent DM patients with no sex or age differences<sup>58</sup>. LUT dysfunction is characterized as reduced bladder sensation and impaired emptying function due to detrusor underactivity<sup>59-61</sup>.

### *Peripheral neuropathy after pelvic surgery*

No good epidemiological studies on the incidence of LUT dysfunction related with peripheral nerve injury in pelvic surgery were performed. Neurogenic LUT dysfunction occurs in 30-50% of patients after extensive pelvic surgery. LUT dysfunction is characterized as reduced bladder sensation, low compliant detrusor and impaired emptying function due to detrusor underactivity<sup>29</sup>.

## References

1. de Groat WC, Booth AM, Yoshimura N. Neurophysiology of micturition and its modification in animal models of human disease. In: Maggi CA, ed. The autonomic nervous system, Vol. 3, Nervous control of the urogenital system. London: Harwood Academic Publishers, 1993: 227-290.
2. Yoshimura N, de Groat WC. Neural control of the lower urinary tract. *Int J Urol* 1997; 4: 111-125.
3. Yoshimura N, Seki S, Chancellor MB. Integrated physiology of the lower urinary tract. In: orcos J, Schick E, eds. Textbook of the neurogenic bladder. Adults and children, Martin Dunitz Ltd, London, UK, 2005: 73-87
4. Andersson K-E. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. *Pharmacol Rev* 1993; 45: 253-308.
5. Park JM, Bloom DA, McGuire EJ. The guarding reflex revisited. *Br J Urol* 1997; 80: 940-945.
6. Fedirchuk B, Hochman S, Shefchyk SJ. An intracellular study of perineal and hindlimb afferent inputs onto sphincter motoneurons in the decerebrate cat. *Exp Brain Res* 1992; 89: 511-516.
7. Holstege G, Griffiths D, De Wall H, Dalm E. Anatomical and physiological observations on supraspinal control of bladder and urethral sphincter muscles in the cat. *J Comp Neurol* 1986; 250: 449-461.
8. Kohama T. [Neuroanatomical studies on the urine storage facilitatory areas in the cat brain. Part I. Input neuronal structures to the nucleus locus subcoeruleus and the nucleus reticularis pontis oralis]. *Nippon Hinyokika Gakkai Zasshi* 1992; 83: 1469-1477.
9. Blok BF, Holstege G. Direct projections from the periaqueductal gray to the pontine micturition center (M-region). An anterograde and retrograde tracing study in the cat. *Neurosci Lett* 1994; 166: 93-96.
10. Blok BF, De Weerd H, Holstege G. Ultrastructural evidence for a paucity of projections from the lumbosacral cord to the pontine micturition center or M-region in the cat: a new concept for the organization of the micturition reflex with the periaqueductal gray as central relay. *J Comp Neurol* 1995; 359: 300-309.
11. de Groat WC, Nadelhaft I, Milne RJ, et al. Organization of the sacral parasympathetic reflex pathways to the urinary bladder and large intestine. *J Auton Nerv Syst* 1981; 3: 135-160.
12. Hegde SS, Eglén RM. Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. *Life Sci* 1999; 64: 419-428.
13. Fetscher C, Fleischman M, Schmidt M, et al. M(3) muscarinic receptors mediate contraction of human urinary bladder. *Br J Pharmacol* 2002; 136: 641-644.
14. Lundberg JM. Pharmacology of cotransmission in the autonomic nervous system: integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide. *Pharmacol Rev* 1996; 48: 113-178.
15. Bennett BC, Kruse MN, Roppolo JR, et al. Neural control of urethral outlet activity in vivo:

- role of nitric oxide. *J Urol* 1995; 153: 2004-2009.
16. Thor KB, Morgan C, Nadelhaft I, et al. Organization of afferent and efferent pathways in the pudendal nerve of the female cat. *J Comp Neurol* 1989; 288: 263-279.
  17. de Groat WC. Spinal cord projections and neuropeptides in visceral afferent neurons. *Prog Brain Res* 1986; 67: 165-187.
  18. Janig W, Morrison JFB. Functional properties of spinal visceral afferents supplying abdominal and pelvic organs, with special emphasis on visceral nociception. *Prog Brain Res* 1986; 67: 87-114.
  19. Habler HJ, Janig W, Koltzenburg M. Activation of unmyelinated afferent fibres by mechanical stimuli and inflammation of the urinary bladder in the cat. *J Physiol* 1990; 425: 545-562.
  20. Yoshimura N, Seki S, Chancellor MB, et al. Targeting afferent hyperexcitability for therapy of the painful bladder syndrome. *Urology* 2002; 59: 61-67.
  21. Blok BFM, DeWeerd H, Holstege G. The pontine micturition center projects to sacral cord GABA immunoreactive neurons in the cat. *Neurosci Lett* 1997; 233: 109-112.
  22. Blok BFM, Holstege G. Neuronal control of micturition and its relation to the emotional motor system. *Prog Brain Res* 1996; 107: 113-126.
  23. Blok BFM, Willemsen ATM, Holstege G. A PET study on the brain control of micturition in humans. *Brain* 1997; 120: 111-121.
  24. Blok BF, van Maarseveen JT, Holstege G. Electrical stimulation of the sacral dorsal gray commissure evokes relaxation of the external urethral sphincter in the cat. *Neurosci Lett* 1998; 249: 68-70.
  25. Blok BF, Holstege G. The central nervous system control of micturition in cats and humans. *Behav Brain Res.* 1998; 92:119-25.
  26. Blok BF, Sturms LM, Holstege G. Brain activation during micturition in women. *Brain.* 1998; 121: 2033-2042.
  27. Blok BF, Sturms LM, Holstege G. A PET study on cortical and subcortical control of pelvic floor musculature in women. *J Comp Neurol* 1997; 389: 535-544.
  28. Blok BF. Central pathways controlling micturition and urinary continence. *Urology.* 2002; 59(5 Suppl 1):13-17.
  29. Wyndaele, J.J., Castro, D., Madersbacher, H., Chartier-Kastler, E., Igawa, Y., Kovindha, A., Radziszewski, P., Stone, A., Wiesel, P. Neurologic urinary and faecal incontinence. In: *Incontinence, 3rd Edition*, Abrams P, Cardozo L, Khoury S, Wein A (Eds.), Health Publication Ltd, Edition 21, Paris, 2005; 1059-1162.
  30. Madersbacher, H., Wyndaele, J.J., Igawa, Y., Chancellor, M., Chartier-Kastler, E., Kovindha, A. Conservative Management in neuropathic urinary incontinence. In: *Incontinence, 2<sup>nd</sup> Edition*, Abrams P, Khoury S, Wein A (Eds.), Health Publication Ltd, Plymouth, 2002: 697-754.
  31. Siroky, M.B., Krane R.J. Neurologic aspects of detrusor-sphincter dyssynergia, with reference to the guarding reflex. *J Urol* 1982;127: 953-957.
  32. Sakakibara, R., Hattori, T., Yasuda, K., Yamanishi, T.: Micturitional disturbance after acute hemispheric stroke: analysis of the lesion site by CT and MRI. *J Neurol Sci*, 137: 47, 1996
  33. Sakakibara R., Hattori, T., Yasuda, K., Yamanishi, T.: Micturitional disturbance and the pontine tegmental lesion: urodynamic and MRI analyses of vascular cases. *J Neurol Sci*,141: 105, 1996
  34. Horimoto, Y., Matsumoto, M., Akatsu, H., Ikari, H., Kojima, K., Yamamoto, T. et al.: Autonomic dysfunctions in dementia with Lewy bodies. *J'Neural*, 250 :530, 2003
  35. Toba, K., Ouchi, Y, Orimo, H., Iimura, O., Sasaki, H., Nakamura, Y. et al. : Urinary


incontinence in elderly inpatients in Japan: a comparison between general and geriatric hospitals. *Aging*, 81 : 47,1996

36. Ouslander, J.G., Palmer, M.H., Rovner, B.W., German, P.S.: Urinary incontinence in nursing homes: incidence, remission and associated factors. *J Am Geriatr Soc* ,41: 1083, 1993
37. Resnick, N.M., Yalla, S.V., Laurino, E.: The pathophysiology of urinary incontinence among institutionalized elderly persons. *N Engl JMed* , 3201:1, 1989
38. Yoshimura, N., Yoshida, O., Yamamoto, S., Mori, H., Majima, M., Mui, K.: Evaluation of urinary incontinence among the nursing home elderly. *Hinyokika Kiyo*, 37: 689, 1991
39. Martignoni, E., Pacchetti, C., Godi, L., Micieli, G., Nappi, G.: Autonomic disorders in Parkinson's disease. *J Neural Transm Suppl*, 45:11, 1995
40. Hattori, T., Yasuda, K., Kita, K., Hirayama, K.:Voiding dysfunction in Parkinson's disease. *Jpn J Psychiatry Neurol*, 461: 181, 1992
41. Sakakibara, R., Hattori, T., Uchiyama, T., Yamanishi, T.: Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. *J Neurol Neurosurg Psychiatry*, 71: 600, 2001
42. Kirchhof, K., Apostolidis, A.N., Mathias, C.J., Fowler, C.J.:Erectile and urinary dysfunction may be the presenting features in patients with multiple system atrophy: a retrospective study. *IntJ Impot Res*, 15 : 293, 2003
43. Sakakibara, R., Hattori, T., Tojo, M., Yamanishi, T., Yasuda, K.,Hirayama, K. Micturitional disturbance in multiple system atrophy. *Jpn J Psychiatry Neurol*, 47: 591, 1993
44. Sakakibara, R., Hattori, T., Uchiyama, T., Yamanishi, T.: Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. *J Neurol Neurosurg Psychiatry*, 71 : 600, 2001
45. Palace, J., Chandiramani, V.A., Fowler, C.J.: Value of sphincter electromyography in the diagnosis of multiple system atrophy. *Muscle Nerve*, 20: 1396, 1997
46. Bonnet, A.M., Pichon, J., Vidailhet, M., Gouider-Khouja, N., Robain, G., Perrigot, M. et al.: Urinary disturbances in striatonigral degeneration and Parkinson's disease: clinical and urodynamic aspects. *Mov Disord*, 12: 509, 1997
47. Stocchi, K, Carbone, A., Inghilleri, M., Monge, A., Ruggieri, S., Berardelli, A. et al. : Urodynamic and neurophysiological evaluation in Parkinson's disease and multiple system atrophy. *J Neurol Neurosurg Psychiatry*, 62: 507, 1997
48. Sakakibara, R., Hattori, T., Uchiyama, T., Suenaga, T., Takahashi, H., Yamanishi, T. et al.: Are alpha-blockers involved in LUT dysfunction in multiple system atrophy? A comparison of prazosin and moxislyte. *J Auton Nerv Syst*, 79:191, 2000
49. Weld, K.J., Dmochowski, R.R.: Association of level of injury and bladder behavior in patients with post-traumatic spinal cord injury. *Urology*, 55: 490, 2000.
50. Perlow, D.L., Diokno, A.C.: Predicting LUT dysfunctions in patients with spinal cord injury. *Urology*, 18: 531, 1981.
51. Ruutu, M., Lehtonen, T.: Urinary tract complications in spinal cord injury patients. *Ann Chir Gynaecol*, 73: 325, 1984.
52. Ruutu, M., Kivisaari, A., Lehtonen, T.: Upper urinary tract changes in patients with spinal cord injury. *Clin Radiol*, 35: 491,1984.
53. Bemelmans, B.L.H., Hommes, O.R., Van Kerrebroeck, P.E.V., Lemmens, W.A.J. G., Doesburg, W. H. Debruyne, F.M.J: Evidence for early LUT dysfunction in clinically silent multiple sclerosis. *J Urol*, 145 : 1219, 1991
54. Araki, I., Matsui, M., Ozawa, K., Nishimura, M., Kuno, S., Saida, T.: Relationship between urinary symptoms and diseaserelated parameters in multiple sclerosis. *J Neurol*, 249:

1010, 2002.

55. Kim, H. Y, Goodman, Ch., Omessi, E., Rivera, V., Kattan, M.W., Boone, T.B.: The correlation of urodynamic findings with cranial magnetic resonance imaging findings in multiple sclerosis. *J Urol*, 159 : 972, 1998
56. Ukkonen, M., Elovaara, I, Dastidar, P., Tammela, T.L.: Urodynamic findings in primary progressive multiple sclerosis are associated with increased volumes of plaques and atrophy in the central nervous system. *Acta Neurol Scand*, 109: 100, 2004.
57. Koldewijn, E.L., Hommes, O.R., Lemmens, W.A.J.G., Debruyne, F.M.J., Van Kerrebroek, P.E.V.: Relationship between LUT abnormalities and disease-related parameters in multiple sclerosis. *J Urol*, 154: 169, 1995.
58. Frimodt-Moller, C.: Diabetic cystopathy: epidemiology and related disorders. *Ann Intern Med*, 92: 318, 1980.
59. Starer, P., Libow, L.: Cystometric evaluation of bladder dysfunction in elderly diabetic patients. *Arch Intern Med*, 150:810,1990
60. Kaplan, S.A., Te, A.E., Blaivas, J.G.: Urodynamic findings in patients with diabetic cystopathy. *J Urol*,152: 342, 1995.
61. Chancellor, M.B., Blaivas, J.G.: Diabetic neurogenic bladder. In: Chancellor MB, Blaivas JG,(eds): *Practical neur-urology*. Boston, Butterworth-Heinemann, 1995, pp149- 154.

A: storage reflexes



B: voiding reflexes




Figure 1. Neural circuits controlling continence and micturition. A: Storage reflexes, B: Voiding reflexes (Modified from Yoshimura & de Groat<sup>2</sup>)




Figure 2. Sympathetic, parasympathetic, and somatic innervation of the lower urinary tract. (Reproduced from Yoshimura & de Groat<sup>2</sup>)




Figure 3. The central reflex pathways that regulate micturition in normal and spinal-cord-injured cats (Modified from Yoshimura et al<sup>3</sup>)




Figure 4. Classification of neurological lesions

(Modified from Madersbacher et al<sup>30</sup>)




Figure 5. Madersbacher classification system with typical neurogenic lesions (Modified from Madersbacher et al<sup>30</sup>)

Heavy lines symbolize overactivity, thin lines underactive or acontractile and green lines normal function of the relevant structure

## Diagnostic workup - How informative are basic diagnostics, are urodynamics essential?

### Speaker:

Márcio Augusto Averbeck <[marcioaverbeck@gmail.com](mailto:marcioaverbeck@gmail.com)>, Brazil

*Prof. MD, Head of Dept. of Neurourology of the Brazilian Society of Urology (SBU)*

*ICS Neurourology Promotion Committee Member*

*Department of Urology – Mãe de Deus Center Hospital, Porto Alegre/Brazil*

*Urodynamics Unit – Santa Casa Hospital Complex, Porto Alegre/Brazil*

Prof. M.A. Averbeck (Brazil) will inform you about the diagnostic workup:

### Introduction

The lower urinary tract (LUT) has its function related to the storage of urine at low pressure and the normal voiding process, which depends on the effective contraction of the detrusor and synergic relaxation of the urethral sphincter. This activity is regulated by a neural control system in the brain and spinal cord that coordinates the urinary bladder and bladder outlet (1). Neurological diseases, e.g. spinal cord lesions, multiple sclerosis, Parkinson disease, etc, can lead to lower urinary tract dysfunction and its consequences (urinary tract infections, urinary incontinence, stone formation, renal failure, etc).

One interesting point to observe is that lower urinary tract symptoms (LUTS) and long-term complications often do not correlate (2). One of the most fearful complications is renal damage secondary to elevated storage pressure in the bladder (3). In this setting, **the diagnostic workup is important to establish whether the patient with neurological disease has a low or high risk of subsequent complications** (1-4). Suprasacral infrapontine spinal lesions can often cause sustained elevated storage pressure in the bladder, due to a combination of detrusor overactivity and detrusor-sphincter dyssynergia. Fortunately, in all other patients with neurogenic lower urinary tract dysfunction (NLUTD), the risk of renal damage is significantly lower (1). Nowadays, with improved diagnostic workup and development of new treatment strategies, e.g. antimuscarinics, botulinum toxin A, bladder augmentation techniques and intermittent self-catheterization, respiratory diseases became the most frequent (21%) cause of death in patients with spinal cord injury (SCI) (5).


As urodynamics and clinical symptoms often do not correlate, asymptomatic patients can present with abnormal urodynamic findings being so far unrecognised risk factors (6). Changes in urodynamics and subsequent damage to the LUT may antedate clinical symptoms. Therefore, comprehensive urological assessment is essential in patients with NLUTD. Treatment and intensity of follow-up examinations are based on the type of NLUTD (1).

A thorough medical history, including voiding diary, and targeted physical examination is mandatory, before any additional diagnostic investigations are planned. Early diagnosis and

treatment are important to avoid irreversible changes within the LUT, both in congenital and acquired neurological diseases (1).

The diagnostic workup must be aimed to accurately evaluate the status of the detrusor and the sphincter. In these regards, Madersbacher (6) proposed a simple classification focused on therapeutic consequences. This classification describes several NLUTD on the basis of the activity/contractility of the detrusor muscle and external urethral sphincter during voiding and filling phase (Figure 1).

**Figure 1: Madersbacher classification system with typical neurogenic lesions [1,6]\***



\*Adapted from the Guidelines on Neurogenic Lower Urinary Tract Dysfunction, European Association of Urology 2012

### **Patient History**

History taking will guide the physical examination and helps to understand the findings of further investigations, such as urodynamics. A comprehensive history must be focused on both storage and voiding phases.

Present history includes medication currently taken and specific urinary history.

Specific urinary history must address bladder sensation (sensation of bladder fullness, sensation for the urge to void, urgency, urgency incontinence), initiation of micturition (normal, precipitate, reflex, strain, Credé), interruption of micturition (normal, paradoxical, passive), enuresis, mode and type of bladder emptying (catheterization). A voiding diary must always be done, as it provides objective information about day- and night-time voiding

frequency, volume voided, incontinence and urge episodes. It is also useful in patients performing intermittent catheterization (1).

Bowel habits must also be addressed since urinary bladder and rectum share a common embryological origin. Besides, their autonomic and somatic innervations have close similarities and the close neighborhood of these two organ systems let assume that dysfunction in one may influence, also mechanically, the function of the other (7).

Other aspect that should be remembered is the sexual function, as neurogenic diseases may cause impairment of both LUT function and sexuality (1).

There are some symptoms and signs that cause great concern: pain, haematuria, dysuria and fever can mean urinary tract infection and must be promptly addressed.

In regards to the past history, it is important to look for hereditary or familial risk factors, obstetric history, accidents and operations, especially those involving the central nervous system incl. spinal cord and spine as well as surgery on organs in the small pelvis (1). Diseases such as diabetes, syphilis, Parkinsonism, multiple sclerosis and encephalitis must always be investigated.

Validated questionnaires should be used to evaluate quality of life (QoL) and the effects of LUTS on daily activities.

### **Physical Examination**

The motor nerve supply of the LUT is provided by the parasympathetic outflow arising from S2–S4. The external (striated) urethral sphincter is innervated by the pudendal nerve, arising from the Onuf's nucleus in S2-S4.

The physical examination is essential for the reliable interpretation of subsequent urodynamics and must be described comprehensively. All sensations and reflexes in the urogenital area, along with careful testing of the anal sphincter and pelvic floor muscles must be carried out.

Sensations on the sacral dermatomes (S2-S5) must be recorded and specified according to the presence (increased/normal/reduced/absent) and type (sharp/blunt) (8). The study of reflexes (increased/normal/reduced/absent) such as Bulbocavernous reflex, Perianal reflex, Cremasteric reflex and Plantar responses (Babinski) should always be carried out.

Digital rectal examination in male patients can not only provide reliable information on prostate volume and presence of nodules and hardening (one must remember that bladder outlet obstruction and LUTS due to prostate enlargement may occur concomitantly with neurological diseases), but also information on the anal sphincter tone and the ability to contract the anal sphincter voluntarily, both in men and in women.

Careful inspection of genitalia also plays an important role in women, as pelvic organ prolapse might be associated with LUTS incl. post-voiding residual urine.

### **Urodynamics**

Urodynamic study is intended to assess the function (or dysfunction) of the lower urinary tract. It has a great importance in the evaluation of patients with neurogenic lower urinary tract dysfunction, especially to detect risk factors for the upper urinary tract in time, before they cause irreversible changes.

In patients with spinal cord injuries above Th 5 – Th 6, it is important to measure blood pressure during the bladder filling, due to the risk of autonomic dysreflexia (AD). It is a sudden and exaggerated autonomic response, which can cause life-threatening blood hypertension if not properly managed (9).

### ***Preparation***

It is recommended that the patient empties the rectum in the usual way the evening before the investigation (avoid enemas shortly before the investigation).

Drugs that influence the LUT function should be stopped at least 48 hours before (if feasible) or otherwise be considered when interpreting the data obtained.

### ***Technique***

All urodynamic findings must be reported in detail and performed according to the ICS “Good urodynamic practices” (10).

A 2-day-bladder diary is recommended before the urodynamics (8).

Urodynamics comprises several steps, as free uroflowmetry (with assessment of residual urine), filling cystometry, flow pressure study, and electromyography (EMG). Each of the listed procedures has some interesting points for discussion (see below). Video-urodynamics can add benefits to the evaluation of neurogenic patients.

- **Free uroflowmetry and assessment of residual urine**

This is an initial step, which gives a first impression of the voiding function. Free uroflowmetry objectively demonstrates the pattern of urine flow (low, intermittent, normal) and should be repeated 2-3 times before invasive urodynamics (bladder catheterization). Unfortunately, in some circumstances (detrusor underactivity, detrusor-sphincter dyssynergia, etc) the free uroflowmetry cannot be done in the setting of neurogenic lower urinary tract dysfunction, as the patient is not able to void. Whenever it is feasible, the free uroflowmetry should be done. Voiding volumes superior to 100-150 ml are often taken as representative for evaluation.

- **Filling cystometry**

This step is either a single investigation (e.g. to control bladder compliance) or, more often, combined with flow pressure studies and video-urodynamics. Normally, the filling cystometry documents the status of the bladder during the filling phase and is performed with body-warm saline in a temperature-controlled room (1)

Through this phase it is possible to identify pathological signs, as detrusor overactivity, low detrusor compliance, abnormal bladder sensation and urinary incontinence.

Other important parameter that can be obtained from filling cystometry is the “detrusor leak point pressure” (DLPP). DLPP is defined as the lowest detrusor pressure at which urine leakage occurs in the absence of either a detrusor contraction or increased abdominal pressure, and may estimate the risk for renal failure.

- **Pressure flow study**

This step is performed after the filling cystometry and documents the LUT function during the voiding phase. Some pathological findings include detrusor underactivity, detrusor-sphincter dyssynergia, and residual urine.

- **Perineal electromyography (EMG)**

This is an additional tool to evaluate the activity of the pelvic floor muscles during the filling cystometry and pressure flow study, mostly superficial electrodes are used to register a random EMG of the pelvic floor musculature. The correct interpretation may be difficult due to artefacts introduced by other equipment used (1). Nevertheless, the EMG can bring valuable information for the diagnosis of detrusor-sphincter dyssynergia.

- **Video-urodynamics**

Video-urodynamics is the gold standard for urodynamic investigation in patients with neurogenic lower urinary tract dysfunction (1). This is a combination of filling cystometry and pressure flow study with imaging.

### **Provocative tests during urodynamics**

Coughing, triggered voiding, or anal stretch are **provocative tests** to be used during the urodynamics in order to trigger detrusor contraction in the setting of NLUTD.

The “**ice water test**” consists of fast-filling cystometry with cooled saline to distinguish between upper motor neuron lesion and lower motor neuron lesion. Patients with upper motor neuron lesion will develop most probably a reflex detrusor contraction, even when not yet present with normal cystometry (11).

### **Specific uro-neurophysiological tests**

Below are listed some specific tests, performed as part of the neurological work-up (1) in specialised centers:

- EMG (in a neurophysiological setting) of pelvic floor muscles, urethral sphincter and/or anal sphincter;
- nerve conduction studies of pudendal nerve;
- reflex latency measurements of bulbocavernosus and anal reflex arcs;
- evoked responses from clitoris or glans penis;
- sensory testing on bladder and urethra.

## **SUMMARY**

There are typical urodynamic manifestations of neurogenic lower urinary tract dysfunction (NLUTD). They can not be substituted by history, clinical examination or echography.

Non invasive urodynamics (bladder diary, free flow and PVR) have to be done before, together with history and clinical examination, as they are the basis for interpretation of the urodynamic curves.

Typical urodynamic findings in patients with NLUTD include:

- Changes in bladder sensitivity (hyposensitivity, hypersensitivity, vegetative sensation/dysaesthesia)
- Low compliance
- Detrusor overactivity (spontaneous or provoked)
- Detrusor underactivity or acontractility
- Detrusor-sphincter dyssynergia
- Sphincter underactivity (can be suspected through EMG findings and incontinence during filling cystometry)

These signs warrant further neurological evaluation, as LUTD may be the presenting symptom of NLUTD (1).

Urodynamics are definitely an important diagnostic tool for patients with neurogenic LUT dysfunction. However, in contrast to spinal cord lesions, urodynamics may not be essential in some patients with cerebral diseases, especially when the upper urinary tract is normal and no significant post-void residual urine is present.

## **REFERENCES:**

1. Guidelines on Neurogenic Lower Urinary Tract Dysfunction, European Association of Urology 2011

2. Nosseir M, Hinkel A, Pannek J. Clinical usefulness of urodynamic assessment for maintenance of bladder function in patients with spinal cord injury. *Neurourol Urodyn* 2007;26[2]:228-33.
3. Gerridzen RG, Thijssen AM, Dehoux E. Risk factors for upper tract deterioration in chronic spinal cord injury patients. *J Urol* 1992 Feb;147[2]:416-8.
4. Hackler RH. A 25-year prospective mortality study in the spinal cord injured patient: comparison with the long-term living paraplegic. *J Urol* 1977 Apr;117[4]:486-8.
5. Lidall IB, Snekkevik H, Aamodt G, et al. Mortality after spinal cord injury in Norway. *J Rehabil Med* 2007 Mar;39[2]:145-51.
6. Madersbacher H. The various types of neurogenic bladder dysfunction: an update of current therapeutic concepts. *Paraplegia* 1990 May;28(4):217-29.
7. Averbeck MA, Madersbacher H. Constipation and LUTS - how do they affect each other? *Int Braz J Urol*. 2011 Jan-Feb;37(1):16-28.
8. Stöhrer M, Goepel M, Kondo A, et al. The standardization of terminology in neurogenic lower urinary tract dysfunction: with suggestions for diagnostic procedures. International Continence Society Standardization Committee. *Neurourol Urodyn* 1999;18(2):139-58.
9. Assadi F, Czech K, Palmisano JL. Autonomic dysreflexia manifested by severe hypertension. *Med Sci Monit* 2004 Dec;10(12):CS77-9.
10. Schäfer W, Abrams P, Liao L, Mattiasson A, Pesce F, Spangberg A, Sterling AM, Zinner NR, van Kerrebroeck P; International Continence Society. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. *Neurourol Urodyn*. 2002;21(3):261-74.]
11. Geirsson G, Fall M, Lindström S. The ice-water test—a simple and valuable supplement to routine cystometry. *Br J Urol* 1993 Jun;71(6):681-5.

## **HOW TO MAINTAIN NORMAL RENAL FUNCTION, HOW TO ACHIEVE CONTINENCE, HOW TO MANAGE INCONTINENCE**

### **THERAPEUTIC STRATEGIES in 2013**

H. Madersbacher (Innsbruck, Austria)

The two aims in the management of patients with neurogenic lower urinary tract dysfunction (LUT-dysfunction) are (1) to protect the upper urinary tract to guarantee adequate (normal) life expectancy, and (2) achieve continence or to manage incontinence for improving their quality of life.

The most important objective is to achieve a safe situation urodynamically, which requires a bladder of sufficient capacity, filling at low pressure and emptying fully without hyperpressure or obstruction of the outlet. The indication for a therapeutic option must be based on the underlying pathophysiology, on risk-factors involved, however, also disease specific considerations as well as the abilities and the needs of the individual patient must be taken into account.

Depending on the localization and the extent of the neurological lesion, the detrusor and sphincter may react either with overactivity or underactivity (acontractility), mostly both, detrusor and sphincter, are affected.

## THE MANAGEMENT OF THE OVERACTIVE DETRUSOR

- + overactive sphincter
- + underactive sphincter
- + normal sphincter

Thomas M. Kessler (Zürich, Switzerland)


According to the ICS terminology 2002, detrusor overactivity is a urodynamic observation characterized by involuntary detrusor contractions during the filling phase which may be spontaneous or provoked. There are 2 patterns of detrusor overactivity, i.e. (1) phasic detrusor overactivity defined by a characteristic wave form, and it may or may not lead to urinary incontinence, and (2) terminal detrusor overactivity defined as a single involuntary detrusor contraction occurring at cystometric capacity, which cannot be suppressed, and leads to incontinence usually resulting in bladder emptying (voiding).

There is no lower limit for the amplitude of an involuntary detrusor contraction but confident interpretation of low-pressure waves (amplitude smaller than 5 cmH<sub>2</sub>O) depends on high-quality urodynamic technique.

There are several reasons for an overactive detrusor. In the context of a neurological disorder, detrusor overactivity is usually observed in patients with a suprasacral lesion. The management of the overactive detrusor depends also on the function/dysfunction of the sphincter and whether the lesion is complete or incomplete.

### 1. MANAGEMENT OF THE OVERACTIVE DETRUSOR COMBINED WITH AN OVERACTIVE SPHINCTER

In patients with suprasacral and infrapontine lesions, the bladder and the striated sphincter as well as the pelvic floor musculature are overactive. Detrusor sphincter dyssynergia is the main problem and puts at risk the upper urinary tract due to low compliance and/or high intravesical pressures during the storage and voiding phase. However, the overactive sphincter provides urinary continence once detrusor overactivity is under control and regular bladder emptying is achieved. Thus, the therapeutic concept is to treat detrusor overactivity and to assist or accomplish bladder emptying.



#### ***How to manage detrusor overactivity***

- Behavioral treatment: includes lifestyle modifications, prompted voiding, timed voiding (bladder training), biofeedback for supporting the voiding pattern modification.
- Antimuscarinics: are the pharmacological first line treatment of detrusor overactivity. Eight antimuscarinics (darifenacin, fesoterodine, imidafenacin, oxybutynin, propiverine, solifenacin, tolterodine, trospium chloride) with different dosages, formulations, and routes of administration are currently used for treating detrusor overactivity. Although there is a huge number of randomized trials for patients

without an underlying neurological disorder, high-level evidence is limited in neurogenic detrusor overactivity. There are differences in efficacy and especially adverse event profiles of the different antimuscarinics and an individualized pharmacological approach seems warranted but there are no clear-cut findings regarding the first choice antimuscarinic for treating neurogenic detrusor overactivity.

- Non invasive neuromodulation: Percutaneous tibial nerve stimulation, transcutaneous tibial nerve stimulation, transcutaneous electrical nerve stimulation of the pudendal nerve (clitoral/penile or intravaginal electrical stimulation) may be considered, especially in patients with MS or incomplete SCI but further high-evidence level studies are necessary.
- Intradetrusor injections of botulinum neurotoxin type A: are a generally accepted and widely used second-line treatment for neurogenic detrusor overactivity. Although several types of botulinum toxin are available, only onabotulinumtoxinA (Botox®) is currently FDA approved for treating neurogenic detrusor overactivity incontinence and a dose of 200 units Botox® is generally recommended.
- Sacral neuromodulation: is a well-established second-line therapy for non-neurogenic lower urinary tract dysfunction, i.e. non-obstructive chronic urinary retention, urgency-frequency syndrome, and urgency incontinence. There is evidence indicating that sacral neuromodulation may also be effective and safe for patients with neurogenic lower urinary tract dysfunction (including detrusor overactivity and detrusor sphincter dyssynergia) but the number of investigated patients is low and there is a lack of randomized, controlled trials. In neurological patients, this treatment should only be offered within well-designed studies in specialized centers.
- Bladder augmentation: due to the afore-mentioned treatment options bladder augmentation is rarely necessary nowadays. Nevertheless, it is still an excellent option in some highly selected patients.
- Urinary diversion: In the case that all other treatments fail, i.e. as an “ultima ratio”, urinary diversion (usually combined with cystectomy) have to be considered (for instance, a patient with refractory urinary incontinence and anatomical low-compliance bladder). The type of urinary diversion (orthotopic bladder substitute (usually not indicated due to the overactive sphincter with consecutive post void residual), heterotopic bladder substitute (continent catheterizable reservoir), ileal conduit) depends on the course of the underlying neurological disorder and the patient’s manual dexterity.


### **How to empty the bladder**

- Alpha-blockers: may be successful for decreasing bladder outlet resistance, post void residual, and autonomic dysreflexia. Alpha-blockers are worth trying out.
- Intermittent (self-)catheterization: see handout Prof. H. Madersbacher.

- Indwelling transurethral / suprapubic catheter: see handout Prof. H. Madersbacher.
- Sacral neuromodulation: see above.
- Intra-sphincter injections of botulinum neurotoxin type A: Although intra-detrusor injections for treating neurogenic detrusor overactivity is a highly recommended treatment, intra-sphincter injection is not due to limited effectiveness.
- Sphincterotomy: decreases the bladder outlet resistance but also increases the risk for urinary incontinence requiring management by external devices (condom catheters, pads, diapers). In addition, sphincterotomy needs to be repeated at regular intervals in many patients. Considering the other treatment options available, sphincterotomy becomes rarely necessary.
- Intraurethral stents: Although the results are comparable with sphincterotomy, the costs, possible complications and re-interventions are limiting factors.
- Urinary diversion: see above.

## 2. MANAGEMENT OF THE OVERACTIVE DETRUSOR COMBINED WITH AN UNDERACTIVE SPHINCTER

Detrusor overactivity combined with an underactive sphincter results in detrusor overactivity incontinence combined with stress incontinence due to the decreased outlet resistance. The therapeutic concept is to treat detrusor overactivity (see above) and to increase the outlet resistance.




### ***How to manage stress incontinence***

- Pelvic floor muscle exercise: may be helpful in patients with incomplete lesions and can be combined with other treatment options (electrostimulation, duloxetine etc.).
- Electrostimulation: High evidence-level studies for neurological patients are lacking. Nevertheless, considering the favorable adverse event profile, electrostimulation may be tried out in patients with incomplete lesions.
- Duloxetine: Although there are no high-evidence level studies in neurological patients, duloxetine may be successful in mild stress incontinence.
- Bulking agents: are not recommended outside of well-designed clinical trials due to the lack of high evidence-level studies in neurological patients.

- Suburethral slings: are established in women, for men the artificial urinary sphincter is the first choice.
- Artificial urinary sphincter: gold standard in severe stress incontinence.

### 3. MANAGEMENT OF THE OVERACTIVE DETRUSOR COMBINED WITH A NORMAL SPHINCTER

Patients with suprapontine lesions usually present with detrusor overactivity combined with a normal sphincter. Typically, there is a synergic function of the detrusor and sphincter, i.e. there is generally no relevant post void residual. Thus, the therapeutic concept is treat detrusor overactivity (see above).



#### References related to the topic and worthwhile to read

Abrams P et al. The standardisation of terminology of lower urinary tract function. *Neurourol Urodynam* 2002; 21: 167-178.

Duthie JB et al. Botulinum toxin injections for adults with overactive bladder syndrome. *Cochrane Database Syst Rev* 2011; CD005493.

Fowler CJ et al. Pelvic organ dysfunction in neurological disease. Clinical management and rehabilitation. Cambridge University Press 2010.

Kessler TM et al. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. *Eur Urol* 2010; 58: 865-74.

Madhuvrata P et al. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. *Eur Urol* 2012; 62: 816-30.

Pannek J et al. Guidelines on neurogenic lower urinary tract dysfunction. EAU 2011. [www.uroweb.org/gls/pdf/20\\_Neurogenic%20LUTD\\_LR.pdf](http://www.uroweb.org/gls/pdf/20_Neurogenic%20LUTD_LR.pdf)

## THE MANAGEMENT OF THE UNDERACTIVE / ACONTRACTILE DETRUSOR

- + underactive sphincter
- + overactive sphincter
- + normal sphincter


Helmut Madersbacher (Innsbruck, Austria)

*According to ICS terminology (2002) detrusor underactivity is defined as a contraction of reduced strength and/or duration, resulting in prolonged bladder emptying and/or a failure to achieve complete emptying within a normal timespan. Acontractile detrusor is one that can not be demonstrated to contract during urodynamic studies. Although not defined by the ICS as a detrusor with a maximum detrusor pressure (pdetr. max.) below 30 cm H<sub>2</sub>O in men and 15 cm H<sub>2</sub>O in women can be considered to be underactive.*

The reasons for an underactive detrusor are several. In the context of neuropathology detrusor acontractility or detrusor underactivity are usually observed with damage of (1) the lumbosacral spinal cord, (2) the bladder peripheral efferent pathways, (3) the bladder peripheral afferent pathways and (4) maybe due to a secondary myogenic failure. There are various options for the management of the underactive /acontractile detrusor, depending also on the function/dysfunction of the sphincter and whether the lesion is complete or incomplete.

### 1. MANAGEMENT OF THE ACONTRACTILE / UNDERACTIVE DETRUSOR COMBINED WITH AN UNDERACTIVE (INCOMPETENT) SPHINCTER

*In complete lesions, the bladder and the striated sphincter as well as the pelvic floor musculature are acontractile. As the bladder capacity is high and the intravesical pressure is low, the kidneys are not at risk as long as regular low pressure emptying is provided. However, neurogenic stress incontinence due to the incompetent sphincter is a problem.*



Sacral / Subsacral  
Spinal Lesion

#### **How to empty the bladder**

- **Bladder expression**

Bladder expression has been recommended since a long time for these patients. With bladder expression (Valsalva or Credé manoeuvre) often unphysiologic high intravesical pressures are created. The reasons for difficulties in expressing the urine from the bladder are the difficulties to open the bladder neck and a functional obstruction at the level of the pelvic floor despite complete flaccid paralysis, resulting in deformation and narrowing of the membranous urethra (Madersbacher, 1975).

Therefore, bladder expression is potentially hazardous for the urinary tract. Before recommending bladder expression it must be proved that the situation in the LUT is urodynamically safe. Contraindications, such as vesico-uretero-renal reflux, prostatic reflux, urethral pathology, hernias, have to be excluded. **In general, bladder expression should be replaced by CIC in most patients.** Alpha-blockers may facilitate voiding, however, urinary stress incontinence may be induced or increased. Therefore Valsalva and Credé only guarantee a good quality of life and are cost

effective in long term when the indication is proper and when the situation remains stable throughout the years, best controlled by (video-)urodynamics.

- **Pharmacotherapy**

So far there is no randomized controlled study which proves the efficacy of cholinergics. They are not able to induce/increase detrusor contractions, however they seem to increase the muscle tone of the detrusor. The patient may feel the bladder at a lower filling volume. Lowering of outflow resistance is another option to facilitate bladder expression. However, there is no controlled trial, which really proves the efficacy of alpha-blockers. Dosages of spasmolytics needed for the relaxation of striated sphincter are often not tolerated because of side effects, especially general muscle weakness.

- **Intermittent catheterisation**

In complete lesions with detrusor acontractility therefore for many patients the method of choice to empty the bladder is intermittent catheterisation, either using the sterile or the hygienic technique.

- In **incomplete lesions** with preserved afferent fibres, **intravesical electrostimulation (IVES)** is useful to induce or to improve sensitivity and contractility of the detrusor (s. below).

### ***How to manage neurogenic stress incontinence***

The other problem with this type of neurogenic LUT dysfunction is the underactive, incompetent sphincter causing neurogenic urinary stress incontinence.

- **Behavioural therapy**

Neurogenic urinary stress incontinence can be improved to a certain degree by regular bladder emptying, controlled fluid intake and the avoidance of urinary tract infections.

- **Pharmacotherapy**


There is no controlled trial which really proves the efficacy of  $\alpha$ -adrenergics in neurogenic urinary stress incontinence. Whether the 5-HT and NA-Reuptake inhibitor Duloxetine is able to improve neurogenic stress incontinence in incomplete lesions, still needs to be proved through studies.

- **Surgery**

Especially in “walkers” continence can only be restored through operative treatment. Although the design of the artificial sphincter has improved considerably over the years, there is still a complication rate of about 30 % in these patients on the long term. In women the risk of erosion at the bladder neck is high, overall long-term continence is satisfactory with about 90 % (Venn et al., 2000). Prerequisites for the implantation of an artificial urinary sphincter is neurogenic stress incontinence, an acontractile detrusor (can be achieved by pharmacotherapy or other procedures), a motivated patient and adequate manual dexterity. Moreover, the system has to be replaced between 10 and 15 years after implantation. For women sling procedures (fascial slings) are also recommended.

- **Condom catheters and external appliances**

Despite all efforts, some patients with neurogenic bladder and urinary incontinence need some kind of assistance to gain social continence. In males, a condom catheter (CC) has been one of the choices. Until now, a wide variety of condom catheters has been available, such as a simple thin latex, plastic or silicon condom catheters or a condom catheter with a double rows of convulsions near the catheter tip to prevent kinking, with an inner flap to prevent the backflow of the urine to the shaft of the penis and an inner wall coated with a self-adhesive. Even a special condom with a passage for catheterization without removal of the condom has been developed. Condom catheters still play a role in the control of urinary incontinence in male patients. Long-term use may cause bacteriuria, but does not increase the risk of UTI compared to other methods of bladder management. Complications may occur less often if the condom catheter is applied properly, and if all hygienic measures necessary are taken, i.e. frequent (daily) change of the condom catheter and maintenance of a low bladder pressure. To prevent a latex allergy, which is becoming more and more common, a silicone condom catheter should be used. To prevent compressive effects the proper size of the condom catheter with self-adhesive is recommended. Moreover, in order to prevent bladder and upper urinary tract damages regular bladder emptying with low bladder pressure and low PVU should be pursued also when a condom catheter is used. In incomplete lesions pelvic floor reeducation may help in the individual patient.




## 2. MANAGEMENT OF THE ACONTRACTILE / UNDERACTIVE DETRUSOR COMBINED WITH AN OVERACTIVE (“SPASTIC”, “HYPERREFLEXIC”) SPHINCTER

This pattern can be seen with lesions at the conal and epiconal level of the spinal cord, e.g. in myelodysplastic children. The main problem is bladder emptying, the overactive sphincter secures continence, provided that the bladder is emptied regularly.

- **Intermittent (Self-)catheterisation**

This dysfunctional pattern is a clear indication for intermittent (self-) catheterisation which provides regular bladder emptying with low pressure and the spastic sphincter secures continence in between.

In **incomplete lesions** the underactive and hyposensitive detrusor is a good indication for intravesical electrostimulation (see below) to achieve bladder sensitivity, however, balanced voiding is mostly not achieved due to sphincter spasticity. Lowering of outflow resistance caused by the spastic striated sphincter is difficult to achieve (see above). Sacral nerve stimulation (SN5) should be considered to improve voiding (referral to a specialized center).



## 3. MANAGEMENT OF THE ACONTRACTILE / UNDERACTIVE DETRUSOR COMBINED WITH A NORMALLY FUNCTIONING SPHINCTER

This pattern is seen with peripheral lesions of bladder innervation especially after pelvic surgery. As the pelvic plexus contains both parasympathetic and sympathetic fibres, decreased parasympathetic innervation may result in decreased detrusor contractility or acontractility, while impaired sympathetic transmission results in incomplete bladder neck closure with weakness of the smooth muscle sphincter. After pelvic surgery urinary retention may occur and **intermittent catheterisation** is the method of choice, however reeducation of the bladder should be aimed as the **lesions are mostly incomplete**. Again **intravesical electrostimulation** is the method of choice to achieve or to speed up bladder rehabilitation. Also cholinergics in combination with alphablockers and with regular bladder emptying may be successful to achieve balanced voiding. Also sacral nerve stimulation should be considered to improve detrusor function (referral to a specialized center).

#### **4. MANAGEMENT OF DETRUSORACONTRACTILITY IN THE SPINAL CORD INJURED PATIENT DURING THE SPINAL SHOCK PHASE**

*The acute phase of the spinal cord lesion is characterized by the “spinal shock phase” with absent spinal reflexes below the lesion. The bladder is able to store urine, but the patient unable to void; unless appropriate measures are taken, overflow incontinence with bladder-overdistention, urinary tract infections and damage to the upper urinary tract will occur. Prevention of early complications, such as bladder overdistention, urinary tract infections, stone formations and urethral injury is a prerequisite for successful rehabilitation of lower urinary tract dysfunction.*

Securing of bladder emptying is of paramount importance. This can be done by intermittent catheterisation (IC), by a suprapubic catheter (SC) or by a transurethral indwelling catheter (ID), rarely adequate spontaneous voiding is possible in incomplete lesions.

**Intermittent catheterisation** has proved to have the lowest complication rate. The alternative of first choice is a **suprapubic catheter**, connected to a urine drainage bag. Only if a suprapubic catheter is contraindicated (injuries in the small pelvis, acute abdomen, pregnancy) **transurethral indwelling catheterisation** is indicated.

However, despite daily catheter care, changing of the catheter each week, continuous drainage into a closed urine collecting device and fixation of the penis at the abdomen near the groin to avoid a decubital ulcer in the urethra at the peno-scrotal angle, the rate of complications is high. Any catheter should be removed as soon as possible based on a daily decision.

#### **5. LONG TERM-INDWELLING TRANSURETHRAL AND SUPRAPUBIC CATHETERS**

The long-term use of indwelling catheters for the management of neuropathic bladder is not favorable due to unavoidable complications. In chronic patients, acceptable indications include impossibility to perform IC, uncontrollable urinary incontinence with problems in wearing continence devices (condom catheters) and in patients with an acute situation in the upper urinary tract including urosepsis. For long-term use, in general, a suprapubic catheter is preferable.

---

### **References related to the topic and worthwhile to read:**

1. Wyndaele JJ, Kovindha A, Madersbacher H et al.: Neurologic Urinary and Faecal Incontinence – In: Incontinence, Edts. Paul Abrams, Linda Cardozo, Saad Khoury, Alan Wein, 4<sup>th</sup> Edition 2009, p. 793-960, Health Publications Ltd. 2009.
  - a. Bladder management for adults with spinal cord injury: a clinical practice guideline for health-care providers. *J Spinal Cord Med* 2006; 29: 527-73.
2. Generao SE, Dall'era JP, Stone AR and Kurzrock EA. Spinal cord injury in children: long-term urodynamic and urological outcomes. *J Urol* 2004; 172: 1092-4, discussion 1094.
3. Kovindha A, Mai WN and Madersbacher H. Reused silicone catheter for clean intermittent catheterization (CIC): is it safe for spinal cord-injured (SCI) men? *Spinal Cord* 2004; 42:638-42.
4. Feifer A, Corcos J: Management of neurogenic bladder with suprapubic cystostomy. – In: *Textbook of the neurogenic bladder*. Edts. Jacques Corcos & Erik Schick, 2nd Edition, p. 564-569, Informa UK Ltd. 2008.
5. Madersbacher H. Intravesical electrical stimulation for the rehabilitation of the neuropathic bladder. *Paraplegia* 1990;28:349-352.
6. Madersbacher G H, Katona F, Berényi M: Intravesical electrical stimulation of the bladder. – In: *Textbook of the neurogenic bladder*. Edts. Jacques Corcos & Erik Schick, 2nd Edition, p. 624-629, Informa UK Ltd. 2008.
7. Wallace PA, Lane FL, Noblett KL. Sacral nerve neuromodulation in patients with underlying neurologic disease. *Am J Obstet Gynecol* 2007;197:96 e91-95.
8. van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, Lycklama a Nijholt AA, Siegel S, Jonas U, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. *J Urol* 2007;178:2029-2034.

